Molecular staging for patients with malignant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Surgical Pathology

Background:

• Routine histology for cancer staging, particularly regional-nodal status, has limitations in detecting low-volume disease.
• Advanced molecular techniques like reverse transcriptase-PCR (RT-PCR) offer significantly higher sensitivity than traditional methods.
• The clinical relevance of micrometastatic disease detected by sensitive assays in sentinel lymph nodes (SLNs) remains a critical question.

Purpose of the Study:

• To evaluate the accuracy and prognostic value of molecular staging in melanoma patients.
• To compare the effectiveness of routine histology, immunohistochemistry, and RT-PCR for detecting metastatic disease in SLNs.
• To determine the clinical relevance of micrometastatic disease identified by molecular assays in melanoma SLNs.

Main Methods:

• A study involving 311 melanoma patients with tumors >0.75 mm thickness.
• Sentinel lymph nodes (SLNs) were analyzed using routine histology, immunohistochemical staining, and a tyrosinase probe-based RT-PCR assay.
• Patient outcomes, including disease-free survival (DFS) and overall survival (OS), were tracked.

Main Results:

• Patients with SLNs negative by all three methods showed high survival rates (92% DFS, 97% OS).
• Patients upstaged by RT-PCR had significantly lower DFS and OS compared to SLN-negative patients.
• Melanoma patients whose SLNs showed metastatic disease by routine histology had a 48% recurrence rate at 5 years.

Conclusions:

• Molecular staging of SLNs in melanoma provides critical prognostic information.
• Micrometastatic disease in SLNs, often missed by histology, is clinically relevant.
• Molecular staging has the potential to improve cancer staging accuracy, prognostication, and adjuvant therapy decisions.